Market Trends of Huntington's Disease Treatment Industry
Symptomatic Treatment Segment is Expected to Hold a Major Market Share Over the Forecast Period
Symptomatic therapeutic development majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington's disease, for which most therapeutic studies have been conducted. Relatively high availability and usage rates of symptom management therapeutics are expected to account for a significant share during the forecast period. The rising need for multiple treatments and the intervention of a multispecialty care team for symptomatic management resulting in additional expenses may contribute to the development of the segment over the forecast period.
Key factors such as rising awareness campaigns and increasing product developments by various market players are expected to contribute to the growth of the segment. For instance, in November 2022, Neurocrine Biosciences Inc. reported additional findings from the Phase 3 KINECT-HD study investigating Valbenazine for treating chorea associated with Huntington's Disease (HD). According to the company, Valbenazine showed a statistically significant improvement over the placebo in the Total Maximal Chorea (TMC) score. In September 2022, Teva Pharmaceutical launched the Honestly HD website to help people better understand what to expect from Huntington's Disease (HD) chorea, one of HD's most apparent and curable symptoms, and how to communicate to their doctor about maintaining independence. Therefore, continuous R&D activities and awareness programs by key players are expected to create lucrative opportunities for the segment during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period due to the rising incidence of Huntington's disease, the presence of key players, and growing R&D funding by the government. According to data published by Cleveland Clinic in January 2021, Huntington's disease affects about 30,000 Americans annually. The report also mentioned that the disease prevalence in North America was 5.7 per 100,000 people annually. As Huntington's condition becomes more prevalent in this region, demand for efficient treatments is anticipated to rise, driving the growth of the target market throughout the forecast period.
Increasing product development and R&D activities by companies are expected to fuel the market's growth over the forecast period. For instance, in April 2022, PTC Therapeutics launched a Phase 2 trial evaluating PTC518, an investigational treatment for Huntington's disease in the United States. The PIVOT-HD trial, which is split into two parts, will be conducted at clinical facilities worldwide. Before being monitored for 12 weeks, participants will be randomly assigned to either a placebo or PTC518 (approximately three months). The pharmacology and pharmacodynamic effect of PTC518-the interactions between the body and a particular compound-will be evaluated in this first section. The second phase will involve a nine-month follow-up period during which researchers will evaluate PTC518's effects on disease biomarkers. In September 2021, Sage Therapeutics Inc. received fast-track designation by the Food and Drug Administration (FDA) for SAGE-718, a potential HD therapy. In June 2021, Galyan Bio planned to commence a clinical trial in collaboration with Bicoll GmbH for its small molecules candidate that aimed at slowing the progression of Huntington's disease.
As a result, the rising prevalence of the target disease, increased R&D, and supportive regulatory authorities are anticipated to contribute to the market expansion in this region throughout the projection period.
